Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL97054 | 0.77 | KMT2A (0.43) | HPGDALDH1A1LMNAMAPTL3MBTL1 | |
| SCHEMBL1900364 | 0.76 | KMT2A (0.54) | HPGDLMNASMN1; SMN2TP53L3MBTL1 | |
| SCHEMBL7301446 | 0.76 | MME (0.44) | HPGDALDH1A1MAPTPOLB | |
| SCHEMBL1416028 | 0.76 | ALDH1A1 (0.45) | HPGDALDH1A1LMNAMAPTPOLB | |
| SCHEMBL11575708 | 0.75 | SMN1; SMN2 (0.53) | HPGDALDH1A1CYP1A2LMNAMAPT | |
| SCHEMBL28037255 | 0.75 | MAOB (0.45) | CYP1A2CYP3A4RAB9A | |
| SCHEMBL3984572 | 0.75 | SPHK2 (0.42) | HPGDCYP1A2MAPTSMN1; SMN2CYP2C19 | |
| SCHEMBL3982704 | 0.75 | TSHR (0.46) | HPGDALDH1A1SMN1; SMN2POLBL3MBTL1 | |
| SCHEMBL4904390 | 0.74 | GAA (0.39) | ALDH1A1CYP1A2LMNAMAPTCYP3A4 | |
| SCHEMBL2477345 | 0.74 | HTR2C (0.48) | ALDH1A1CYP1A2LMNASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2005002514-A2 | COMPOUNDS HAVING INHIBITIBE ACTIVITY OF PHOSPHATIDYLINOSITOL 3-KINASE AND METHODS OF USE THEREOF | ECHELON BIOSCIENCES INCORPORATED (US) | 2005-01-13 | — | — | WO | claimed |
| US-6262098-B1 | ISOXAZOLE ESTROGEN RECEPTOR AGONIST AND ANTAGONIST | CHIRON CORPORATION | 2001-07-17 | — | — | US | claimed |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-12-26 | — | — | US | disclosed |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2013-02-21 | — | — | US | disclosed |
| EP-2528598-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI - CANCER AGENT | Takeda Pharmaceutical Company Limited (JP) | 2012-12-05 | — | — | EP | disclosed |
| EP-2411034-A1 | PROMOTION OF NEURONAL INTEGRATION IN NEURAL STEM CELL GRAFTS | Life & Brain GmbH (DE) | 2012-02-01 | — | — | EP | disclosed |
| EP-1551412-B1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF DISEASES RELATED TO NEUROTROPHINES | MINERVA PATENTS SA (LU) | 2011-05-04 | — | — | EP | disclosed |
| EP-2260869-A2 | Pharmaceutical product | Takeda Pharmaceutical Company Limited (JP) | 2010-12-15 | — | — | EP | disclosed |
| US-6495604-B1 | SUCH AS D-ETHYL-6-(N-(2,4-DIFLUOROPHENYL)SULFAMOYL)-1-CYCLOHEXENE-1-CARBOXYLATE FOR INHIBITING NITRIC OXIDE AND/OR CYTOKINE PRODUCTION; FOR PREVENTING OR TREATING CARDIAC DISEASE, AUTOIMMUNE DISEASE OR SEPTIC SHOCK | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-12-17 | — | — | US | disclosed |
| EP-1254659-A1 | STABLE EMULSION COMPOSITIONS | Takeda Chemical Industries, Ltd. (JP) | 2002-11-06 | — | — | EP | disclosed |
| EP-0622361-B1 | Heterocyclic compounds as bradykinin antagonists | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-10-04 | — | — | EP | disclosed |
| EP-1063228-A1 | CYCLOALKENE DERIVATIVES, PROCESS FOR PRODUCING THE SAME, AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-12-27 | — | — | EP | disclosed |
| US-6153771-A | 5-SUBSTITUTED ISOPHTHALIC ACID BIS(ALLYLAMIDE) OR CORRESPONDING EPOXIDE OF THE ALLYL GROUPS; INTERMEDIATE FOR IOHEXOL | NYCOMED IMAGING AS (NO) | 2000-11-28 | — | — | US | disclosed |
| EP-0968173-A1 | PROCESS FOR THE PREPARATION OF IODINATED CONTRAST AGENTS AND INTERMEDIATES THEREFOR | NYCOMED IMAGING AS (NO) | 2000-01-05 | — | — | EP | disclosed |
| US-5824821-A | EPOXIDATION OF ALLYLAMINO COMPOUND, HYDROLYSIS TO YIELD 2,3-DIHYDROXYPROPYLAMINO COMPOUNDS | NYCOMED IMAGING AS (NO) | 1998-10-20 | — | — | US | disclosed |
| WO-1998034905-A1 | PROCESS FOR THE PREPARATION OF IODINATED CONTRAST AGENTS AND INTERMEDIATES THEREFOR | NYCOMED IMAGING AS (NO) | 1998-08-13 | — | — | WO | disclosed |
| US-4626528-A | O,O-dialkyl O[p-(N-alkylcarbamoyl)phenyl]phosphorothionates and insecticidal compositions including the same | S. C. JOHNSON & SON, INC. (US) | 1986-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130345304-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | HPGD 1096/4885ALDH1A1 2141/4885CYP1A2 4814/4885 |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | HPGD 1096/4885ALDH1A1 2141/4885CYP1A2 4814/4885 |
| US-20130046000-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | HPGD 1096/4885ALDH1A1 2141/4885CYP1A2 4814/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | HPGD 1096/4885ALDH1A1 2141/4885CYP1A2 4814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.